Circular: Use of Fixed-dose Combinations in Place of Lamivudine Single Agents
Issued following reports of alleged stock outs of 300mg lamivudine in Gauteng, the circular notes that there is no shortage of the tablet but rather that the tablet will no longer be available on tender.
The circular also notes that fixed dose ARV combinations are preferred to single-drug tablets as this reduces patient. The document notes that as 300mg lamivudine tablets will no longer be available on tender, that clinicians should look at replacing 300mg lamivudine for some patients with one of three combination ARVs.
It asks that clinicians reserve the use of the 150mg lamivudine tablets, which will continue to be available, for complicated and paediatric cases.
Download and read the full circular: Use of fixed-dose combinations in place of lamivudine single agents
Download the Department of Health’s statement: There is no shortage of ARVs in Gauteng
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Circular: Use of Fixed-dose Combinations in Place of Lamivudine Single Agents
by healthe, Health-e News
January 9, 2016